CytoSorbents showcases hemoperfusion technologies at EACTS Annual Meeting in Copenhagen.

CytoSorbents Corporation will showcase its blood purification technologies at the European Association for Cardio-Thoracic Surgery Annual Meeting, featuring two scientific presentations and a lunch symposium. The company's sorbent hemoperfusion technologies, including CytoSorb and DrugSorb-ATR, are highlighted as a safety net in cardiac surgery. The meeting is expected to attract over 5,000 attendees.

CytoSorbents Corporation (NASDAQ: CTSO) will present its pioneering blood purification technologies at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, taking place October 8-11, 2025, in Copenhagen, Denmark. The meeting is expected to attract over 5,000 attendees from around the world.

The company's presence at EACTS will feature two high-profile scientific presentations of original data and a Company-sponsored lunch symposium, highlighting the expanding role of its sorbent hemoperfusion technologies as a safety net in cardiac surgery. The presentations and symposium will showcase the clinical impact of CytoSorb® and DrugSorb™-ATR, validating their effectiveness in reducing the risk of severe bleeding complications and improving patient outcomes.

Dr. Daniel Wendt, Vice President of Cardiovascular Medical Affairs at CytoSorbents, stated, "We are excited to share new data at EACTS that further validates the important role of CytoSorb® and DrugSorb™-ATR in cardiac surgery. From the first randomized trial results of DrugSorb™-ATR in patients on DOACs to real-world evidence in acute coronary syndrome (ACS) patients undergoing coronary artery bypass grafting (CABG) surgery, our technologies continue to demonstrate significant clinical impact that is helping to change the practice of cardiovascular medicine."

One of the key presentations will be "Intraoperative Removal of Direct Oral Anticoagulants in Patients Undergoing Urgent Cardiothoracic Surgery," presented by Professor Richard Whitlock of McMaster University. This randomized controlled trial data demonstrates that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs) compared to sham control in patients undergoing urgent cardiac surgery.

Another presentation, "Dual Antiplatelet Therapy (DAPT) and Urgent CABG in Acute Coronary Syndrome (ACS): Impact of P2Y12 Inhibitor Choice & Intraoperative Hemoadsorption on Perioperative Bleeding: Comparative Real-World Analysis," will be presented by Professor Matthias Thielmann of the Westerman Heart & Vascular Center. This real-world study shows that combining dual antiplatelet therapy with intraoperative use of CytoSorb® is associated with highly significant reductions in severe bleeding complications compared to patients treated with aspirin + Plavix (clopidogrel) without CytoSorb.

The Company-sponsored lunch symposium, titled "Hemoadsorption as Safety Net in Cardiac Surgery: New Insights," will feature presentations by leading cardiothoracic surgeons from Germany and Italy. Topics will include the potential of hemoadsorption to improve the outcome of endocarditis patients, the combination of venoarterial extracorporeal membrane oxygenation (VA ECMO) with hemoadsorption in cardiogenic shock patients, and evidence from clinical trials on the removal of antithrombotic drugs.

CytoSorbents' technologies are designed to actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption, making them a valuable tool in various critical illnesses, including sepsis, burn injury, trauma, and cardiac surgery. The company's lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date.

CytoSorbents is also developing the DrugSorb™-ATR antithrombotic removal system, which has received two FDA Breakthrough Device Designations for the removal of ticagrelor and direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures.